Videos

Managing these treatments involves many considerations, including glycemic control and nutrition, among others.

A renowned lung cancer pharmacy specialist presents the efficacy and safety data from the phase 3 FLAURA2 trial, emphasizing progression-free survival and overall survival outcomes, and shares additional insights from the MIRAPOSA study.

The study shows that tirzepatide significantly improves secondary outcomes in patients with sleep apnea.

Cara Chang, PharmD, BCOP, examines the prevalence of EGFR positivity, provides an overview of clinically relevant EGFR mutations, and discusses therapeutic options for EGFR-positive mutations.

Tim Mok, PharmD, BCOP, BCPS, discusses innovative therapies that are changing the treatment options available for patients with hematologic malignancies.

Niki Shah Vice President of Impact Innovation and Activation at McKesson, previews the 2024 McKesson ideaShare conference.

American Diabetes Association Scientific Sessions speaker Ivan de Araujo emphasizes the importance of the pharmacist’s role in diabetes care and his hopes for the future of care.

Ryan Haumschild discusses the evolving treatment landscape for patients with multiple myeloma.

Reducing maternal mortality through improving access, screening, education and providing support during pregnancy.

The panelists share their concluding thoughts on the importance of collaboration between academic and community practices to achieve the best outcomes for their patients, which includes seeking second opinions and incorporating insights from tumor board discussions.

Medical experts discuss their perspectives on therapy approval and the significance of formulary inclusion, emphasizing the need to carefully consider both toxicities and benefits, which may ultimately lead to the operationalization of a drug in clinical practice.

Creating a supportive environment and staying informed on the latest research can be significant when supporting patients in the LGBTQ+ community, notes Olivia Buckoski, PharmD, AAHIVP, HIVPCP.

Tune into this episode of “Public Health Matters” to hear Dr. Bolu Oladini’s unconventional journey within pharmacy, his passion for mental health, and how artificial intelligence is beginning to be integrated into health care and everyday life.

The panel concludes by sharing their insights and expressing their aspirations for future developments and improvements in RSV vaccination efforts.

The key opinion leaders examine the current prevalence of RSV infections and its evolution over time, analyzing the seasonal patterns of RSV outbreaks in the United States and identifying the demographic groups most vulnerable to RSV infections.

Key opinion leaders (KOLs) discuss the use of CDK4/6 inhibitors in early breast cancer, specifically in patients who have undergone chemotherapy and surgery. They highlight the key factors that help determine which patients are most likely to benefit from receiving these medications.

The panelists discuss the clinical and economic factors that influence treatment decisions for early breast cancer (eBC), as well as the differences between eBC and metastatic breast cancer (mBC) in terms of adverse event management protocols and strategies for optimizing patient adherence.

Pharmacy technicians can expand their skills to explores career growth.

Expert discusses the challenges faced by pharmacists in palliative and hospice care.

Guidance for pharmacy technicians as they continue to learn and start their careers.

Expert discusses the challenges faced by pharmacists in palliative and hospice care.

Emily Griffin discusses her career in pharmacy and in digital content creation.

Nicolas Girard, MD, PhD, discusses the results of the PALOMA-2 trial, highlighting the subcutaneous (SC) delivery of amivantamab combined with lazertinib as a first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations.

Pharmacists play a crucial role in managing pain for cancer patients in palliative care.

Heather Moore, BCOP, CPP, PharmD, discusses the importance of treatment for early breast cancer, highlighting the use of chemotherapy followed by endocrine therapy. She notes that CDK4/6 inhibitors are being added for higher-risk patients, and oral selective estrogen receptor degraders may also be used in advanced cases.

Frank Scimeca, PharmD, MBA, BCOP, discusses the crucial collaborative effort between academic and community practices in managing and monitoring patients receiving CDK4/6 inhibitors, emphasizing the importance of communication and coordination to ensure optimal patient care.

Medical professionals discuss the ongoing requirements in RSV treatment and vaccination, stressing the importance of at-risk populations maintaining hand hygiene, staying home when sick, and avoiding large crowds during peak seasons to minimize transmission, while also exploring the use of combination tests, panel testing, and rapid testing for RSV diagnosis.

Rodney E. Rohde, PhD, SM, SV, MB (ASCP), FACSc, guides a conversation on patient education materials, recommending resources from the American Pharmacists Association, the Centers for Disease Control and Prevention, and the Advisory Committee on Immunization Practices, which provide tools to inform the public about vaccine-preventable diseases.

Data from the PERSEUS trial supports use of daratumumab in combination with bortezomib, lenalidomide, and dexamethasone followed by daratumumab and lenalidomide maintenance as a new standard of care for patients with newly diagnosed multiple myeloma.

Results from the initial safety run-in of MajesTEC-7 indicate that the combination of teclistamab, daratumumab, and lenalidomide in newly diagnosed multiple myeloma (NDMM) shows a manageable safety profile with early signs of efficacy.